Topics

POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed

13:05 EDT 28 Oct 2019 | SCRIP

Imfinzi and tremelimumab plus chemotherapy improved PFS in first-line NSCLC, but overall survival is continuing to be assessed, and AstraZeneca...

      

Related Stories

 

Original Article: POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed

NEXT ARTICLE

More From BioPortfolio on "POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed"

Quick Search

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...